最新一期业绩显示，2025年一季报，公司实现营业收入3.15亿元，同比-26.58%；净利润1520.18万元， 同比-47.29%，销售毛利率33.85%。 资金流向方面，5月12日，万邦德主力资金净流入93.41万元，近5日总体呈流入状态，5日共流入24.58万 元。 万邦德医药控股集团股份有限公司主营业务为现代中药、化学原料药及化学制剂的研发、生产和销售以 及提供高端医疗器械研制、医疗设备服务和提供医院工程服务。主要产品是心脑血管系统主导产品、神 经系统主导产品、呼吸系统主导产品、消化系统主导产品、精神系统主导产品、骨科植入器械、医疗设 备及医院工程服务、一次性无菌医用高分子耗材、防护用品。 5月12日，万邦德今日收盘5.72元，下跌1.04%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到83.70倍，总市值34.99亿元。 从行业市盈率排名来看，公司所处的化学制药行业市盈率平均45.46倍，行业中值26.94倍，万邦德排名 第127位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)127万邦德83.7063.111.3034.99亿行业平均 45.4645.504.62119 ...

Group 1 - The core viewpoint of the news is that Wanbangde's stock performance and financial metrics indicate a mixed outlook, with a high PE ratio compared to industry averages and a decline in revenue [1][2] - As of April 29, Wanbangde's closing price was 5.81 yuan, with a PE ratio of 64.63, significantly higher than the industry average of 45.68 [1][2] - The company's total market capitalization is 3.583 billion yuan, ranking 119th in the chemical pharmaceutical industry [1][2] Group 2 - In terms of capital flow, Wanbangde experienced a net outflow of 8.5344 million yuan on April 29, with a total outflow of 9.6829 million yuan over the past five days [1] - The latest financial results for 2024 show that the company achieved a revenue of 1.443 billion yuan, a year-on-year decrease of 6.39%, while net profit was 55.441 million yuan, an increase of 12.66% [1] - The company's gross profit margin stands at 41.83%, indicating a relatively healthy profitability despite the revenue decline [1]